{"id":"https://genegraph.clinicalgenome.org/r/48f788db-a9ae-4fc0-b1b4-4c1aebdceb3ev1.0","type":"EvidenceStrengthAssertion","dc:description":"*STK11* was first reported in relation to autosomal dominant Peutz-Jeghers syndrome (PJS) in 1998 (Jenne et al. and Hemmiki et al., PMIDs 9425897 and 9428765). PJS is characterized by the development of gastrointestinal (GI) PJS-type hamartomatous polyps and mucocutaneous hyperpigmentation, which most often presents in childhood and fades by puberty. GI polyps present a significant clinical burden and can cause chronic bleeding and intussusception in individuals with PJS. Individuals with PJS have been reported to have an increased cumulative lifetime risk for various cancers, including female breast cancer, colorectal cancer, stomach cancer, small bowel cancer, pancreatic cancer, lung cancer, endometrial cancer, cervical cancer, non-epithelial sex cord tumors of the ovary, and Sertoli cell testicular tumors. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism or inheritance pattern and phenotypic variability. Therefore, the described phenotypic manifestations and tumor spectrum has been lumped into one disease entity: Peutz-Jeghers syndrome (OMIM: 175200). Fourteen variants (missense, in-frame deletions/insertions, nonsense, frameshift, large deletion, complex rearrangements) that have been reported in 14 probands in 5 publications (PMIDs: 9425897, 9428765, 12865922, 15121768, 30689838) were included in this curation. Variants reported are largely truncations and gross deletions, and additional evidence of familial co-segregation supports their association with PJS. Furthermore, large-scale meta analyses and case control analyses show the association of cancer susceptibility in individuals with PJS (PMIDs: 23415580, 11113065, 16707622). Data from these studies is largely from highly-ascertained cohorts and may overestimate cancer risks. At least one large-scale population-based study contradicts the high risk of breast cancer reported in the literature (PMID: 33471991). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss-of-function. This gene-disease association is also supported by experimental evidence (6 points, PMIDs: 15800014, 10441497, 15261145, 19681070, 12226664, 15987703, 9425897). In non-patient cells (mouse embryonic fibroblasts), deleterious effects such as hyperactivated mTOR signaling was observed when *Stk11* was lost. Mouse models of loss of *Stk11* replicating the human phenotype including mammary tumors and small intestine hamartomatous polyps. In summary, *STK11* is definitively associated with autosomal dominant Peutz-Jeghers syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated as definitive on 2/22/2017 by Colon Cancer GCEP. This re-curation was approved by the ClinGen Hereditary Cancer GCEP on 5/26/2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/48f788db-a9ae-4fc0-b1b4-4c1aebdceb3e","GCISnapshot":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2023-12-20T18:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2023-12-20T22:25:43.111Z","role":"Publisher"}],"curationReasons":["RecurationNewEvidence","RecurationFrameworkChange"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a7c13d6-fea0-4002-a1c8-9dbc63f90f02","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a7c13d6-fea0-4002-a1c8-9dbc63f90f02_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 12552571 -completely inactive in vitro as it is unable to autophosphorylate at Thr336, the major LKB1/STK11 autophosphorylation site, and to phosphorylate the p53 tumour suppressor protein. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1a7c13d6-fea0-4002-a1c8-9dbc63f90f02_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12865922","allele":{"id":"https://genegraph.clinicalgenome.org/r/2f836155-ddc6-4847-8d99-1b98d9c8ed9a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.910C>T (p.Arg304Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/183802"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a365db02-e69f-4e14-8acc-4f686d9affd1","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a365db02-e69f-4e14-8acc-4f686d9affd1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30689838","allele":{"id":"https://genegraph.clinicalgenome.org/r/e6c3653b-99a4-4686-a23f-4c19ea3ad760","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.(?_1218417)_(1219413_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/417315"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3fb8e5d0-ea6c-441f-8a8f-daa6aa01a4eb","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3fb8e5d0-ea6c-441f-8a8f-daa6aa01a4eb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15121768","allele":{"id":"https://genegraph.clinicalgenome.org/r/a56bace1-90b4-4588-b378-cd6c5985785b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.409C>T (p.Gln137Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA022914"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4b2f5cba-4d7e-4ae3-8d62-de15233aa5b5","type":"EvidenceLine","dc:description":"Not counting this since already curated Jenne et al. 1998 paper (first clinical paper, PMID: 9425897). Rest of points for this curation come from PJS cases with breast cancer.","calculatedScore":1.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b2f5cba-4d7e-4ae3-8d62-de15233aa5b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9428765","allele":{"id":"https://genegraph.clinicalgenome.org/r/37c8e604-2317-4e6a-aee1-0da179fc3b97","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.169G>T (p.Glu57Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7447"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/600ff427-6919-4f30-b666-d8b805a0ae0c","type":"EvidenceLine","dc:description":"I am re-scoring this from original score of 1: predicted or proven null variant in an individual meeting clinical dx criteria for PJS, ok to score default. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/600ff427-6919-4f30-b666-d8b805a0ae0c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","allele":{"id":"https://genegraph.clinicalgenome.org/r/d161f910-8279-4fb6-92cd-02a9cb0f6294","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.718_721del (p.Ser240LeufsTer46)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7441"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ce97b349-d89c-4420-9f4a-444bba27fc52","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce97b349-d89c-4420-9f4a-444bba27fc52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15121768","allele":{"id":"https://genegraph.clinicalgenome.org/r/6ce1e7e0-58b8-4939-874f-32a26106863f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.509A>C (p.Gln170Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA402948926"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/64365c1c-f792-449e-8fb6-8d9ffe553355","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64365c1c-f792-449e-8fb6-8d9ffe553355_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16287113","allele":{"id":"https://genegraph.clinicalgenome.org/r/9dd7b19c-844d-44fe-ad01-4490521a12f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.(?_1218407)_(1226657_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/831632"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/faac6ae4-c019-46e2-be54-1e1c7fe6cc66","type":"EvidenceLine","dc:description":"Authors state this subject has a family history of  Peutz-Jeghers syndrome , but do not elaborate further. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faac6ae4-c019-46e2-be54-1e1c7fe6cc66_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","allele":{"id":"https://genegraph.clinicalgenome.org/r/07e260ff-31d4-45aa-8ad3-dd7fe73b2f06","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.465-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7442"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8116bc12-cb62-4959-b51d-f073ce1431f9","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8116bc12-cb62-4959-b51d-f073ce1431f9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9428765","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4c7626f-d592-44d1-b83a-a1e9712c5e3c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.208G>T (p.Glu70Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16044077"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1f1a20e1-b061-4421-97b0-923bb01c830b","type":"EvidenceLine","dc:description":"I am re-scoring this using default based on: predicted or proven null variant identified in an individual with a clinical dx of PJS. OK to use default score in this case. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f1a20e1-b061-4421-97b0-923bb01c830b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","allele":{"id":"https://genegraph.clinicalgenome.org/r/b7ac0f2f-51e3-44a3-986f-cda8468dfe08","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.843del (p.Leu282SerfsTer5)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7440"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/6a2bbe8e-d6b7-4245-9853-413c3598589c","type":"EvidenceLine","dc:description":"Authors state this subject has a family history of  Peutz-Jeghers syndrome , but do not elaborate further. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a2bbe8e-d6b7-4245-9853-413c3598589c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","allele":{"id":"https://genegraph.clinicalgenome.org/r/95d520b4-0e86-4ce6-be28-8fa831e73bcc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.759C>A (p.Tyr253Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7439"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/aad4136f-c790-4a97-92e3-90343e277e07","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aad4136f-c790-4a97-92e3-90343e277e07_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30689838","allele":{"id":"https://genegraph.clinicalgenome.org/r/098a9566-246b-4746-af65-4af93b1c0b09","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.(?_1221949)_(1222006_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/417312"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/6c320998-ad81-4a0a-bd49-e4052ad75f89","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6c320998-ad81-4a0a-bd49-e4052ad75f89_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16287113","allele":{"id":"https://genegraph.clinicalgenome.org/r/b7dd7405-47e5-446c-9f00-71d62fdb0b8b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.(1207204_1218416)_(1219414_1220372)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/982008"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d34d5793-cf26-4f35-82d1-83ddd9cee22f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d34d5793-cf26-4f35-82d1-83ddd9cee22f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15121768","allele":{"id":"https://genegraph.clinicalgenome.org/r/90ad21f8-95a7-4270-9060-d9430f7c760f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000455.5(STK11):c.367C>T (p.Gln123Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA402947913"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2870279-71dc-402d-8699-e88aec365008","type":"EvidenceLine","dc:description":"First large cohort study to assess cancer risk\n240 individuals (international, multicenter) with PJS with confirmed STK11 variants\n\t188 from 49 families, 52 apparently sporadic\n78 unique variants identified (14 truncations, 4 deletions, 15 missense all in kinase domain)\nCalculated cumulative cancer risks:\n\tGI: 66% to age 70y\n\tBreast 32% to age 60y\n\tGyn: 13% to age 60y\n\nThis is not really a case control study; rather, a cohort study to estimate age-related cancer risks in PJS. Not scoring as genetic evidence but keeping in curation as evidence for tumor risk in this syndrome. \n\nNot Scored. ","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2870279-71dc-402d-8699-e88aec365008_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15188174","rdfs:label":"Lim 2004 Cohort study","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/a98c470d-5072-4918-b785-048fa53e20b6","type":"Cohort","allGenotypedSequenced":240,"alleleFrequency":0.1958333333333333,"detectionMethod":"\"Several different techniques were used to identify germline STK11 mutationsâ€”conformational sensitive gel electrophoresis, single-strand conformational polymorphism, denaturing high-performance liquid chromatography, denaturing gradient gel electrophoresis, and direct sequencing of exons.\"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2870279-71dc-402d-8699-e88aec365008_cc_evidence_item"}],"numWithVariant":47,"relatedCondition":{"id":"obo:MONDO_0008280"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/595efc15-fabd-4008-b283-288eba616c54","type":"Cohort","allGenotypedSequenced":0,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2870279-71dc-402d-8699-e88aec365008_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"Other"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9cca9a11-4d4c-443f-a785-e72214348b0d","type":"EvidenceLine","dc:description":"This isn't truly a case control analysis, just comparing to SEER statistics. \nMeta analysis, assessed cumulative risk of cancers in PJS using comaprisons to general population sEER statistics\n210 total patients with PJS\n\nWill assign 1 point for overall tumor risk in PJS; tumors identified included GI, pancreas, lung, breast, testes, ovary, cervix, uterus - this is consistent with the larger Hearle et al. study as well. Replication of same estimated risk of malignancy through these studies. ","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cca9a11-4d4c-443f-a785-e72214348b0d_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11113065","rdfs:label":"Giardello meta analysis case control","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/61702898-d4a1-4887-9fd7-ed5e925ae362","type":"Cohort","allGenotypedSequenced":104,"alleleFrequency":0.1057692307692308,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cca9a11-4d4c-443f-a785-e72214348b0d_cc_evidence_item"}],"numWithVariant":11},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/f96ba483-7cbc-4603-960a-a4dc006082e1","type":"Cohort","allGenotypedSequenced":0,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cca9a11-4d4c-443f-a785-e72214348b0d_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":""}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1afefbcb-023d-4bd6-9d4a-a2b33464f962","type":"EvidenceLine","dc:description":"Similar to Lim et al, this is not really a case control study, rather a cohort study estimating cumulative cancer risks. Not scoring, but listing evidence here for info on tumor risks in PJS.\nAssessed cumulative incidence of cancer in 149 individuals with PJS with confirmed STK11 mutations\n39 cancers found\n40 unique mutations (15 truncating, 8 splicing, 9 deletions, 8 missense)\nGI cancer 63% by age 70y [23-82 CI]\nBreast only 1 case, N/A\nGyn cancer 18% by age 50y [3-32 CI]\n","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1afefbcb-023d-4bd6-9d4a-a2b33464f962_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16407375","rdfs:label":"Mehenni 2006 Cohort study","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/6abe5dad-c018-43d6-a12c-6c2198d71a85","type":"Cohort","allGenotypedSequenced":29,"alleleFrequency":1,"detectionMethod":"SSCP and Sanger sequencing used to detect STK11 variants.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1afefbcb-023d-4bd6-9d4a-a2b33464f962_cc_evidence_item"}],"numWithVariant":29,"relatedCondition":{"id":"obo:MONDO_0008280"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/c730f1f6-9864-48d1-bb48-9d3c11e1c786","type":"Cohort","allGenotypedSequenced":0,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1afefbcb-023d-4bd6-9d4a-a2b33464f962_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"Other"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3126c52b-22c3-4d09-a996-3260f7596a31","type":"EvidenceLine","dc:description":"JHM: This is from previous curation; small cohort only from one population, not scoring. ","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3126c52b-22c3-4d09-a996-3260f7596a31_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23415580","rdfs:label":"Resta Case-Control 1","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/4e6599bd-e1c1-441a-a4bb-39a5652d5675","type":"Cohort","allGenotypedSequenced":119,"alleleFrequency":0.5462184873949579,"detectionMethod":"No variant detection methods indicated.  Just that \"Patients carrying the familial mutation were considered affected, independent of matching the clinical criteria.\"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3126c52b-22c3-4d09-a996-3260f7596a31_cc_evidence_item"}],"numWithVariant":65,"relatedCondition":{"id":"obo:MONDO_0008280"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/2ca5b6f9-6715-482c-94c8-726209149304","type":"Cohort","allGenotypedSequenced":0,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3126c52b-22c3-4d09-a996-3260f7596a31_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"Relative Risk"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/aff1d8c3-d295-4c41-81e4-0abe71f9a583","type":"EvidenceLine","dc:description":"This is the largest non-ascertained cohort to date. The OR found by this study contrasts sharply with ascertained cohorts in the literature, suggesting almost no association with breast cancer versus a very high risk (up to 54% Giardello et al) in other papers. However, the BCAC study did not do CNV analysis; they may be missing a proportion of individuals with gross dels in this gene.","direction":"Contradicts","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aff1d8c3-d295-4c41-81e4-0abe71f9a583_cc_evidence_item","type":"Finding","dc:description":"Not scoring this, as it is assessing only the breast cancer phenotype in PJS. We know the association of STK11 with PJS is definitive; however, this study does provide some contradictory evidence against breast tumors as an associated phenotype in a large, unascertained cohort. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33471991","rdfs:label":"BCAC Population analysis","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/ed615a0a-9e77-4893-ac2d-81388a69ea2e","type":"Cohort","allGenotypedSequenced":48826,"alleleFrequency":0.0001228853479703437,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aff1d8c3-d295-4c41-81e4-0abe71f9a583_cc_evidence_item"}],"numWithVariant":6},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/3fda3c9d-b31a-45aa-85b9-cb095205c5fc","type":"Cohort","allGenotypedSequenced":50703,"alleleFrequency":0.00009861349427055599,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aff1d8c3-d295-4c41-81e4-0abe71f9a583_cc_evidence_item"}],"numWithVariant":5},"lowerConfidenceLimit":0.48,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.5,"statisticalSignificanceType":"","statisticalSignificanceValue":1.6,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":5.28}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/51659aa8-659d-413a-bd38-a8a924c03156","type":"EvidenceLine","dc:description":"JHM: This is not really a case control study, but a cohort study assessing cumulative cancer risks in individuals with PJS. \"Control\" population is using statistics on general population cancer risks. Kaplan Meier statistical methods used to compute. \n\n\n\"A totalof 419 Peutz-Jeghers syndrome patients (193 males and 226 females) ascertained through 225 probands were available for analysis. One hundred ninety-four of the patients were from 93 families (family size range, 2-11) and 132 represented sporadic cases. A germ-line mutation in STK11 was established in 297 of the 419 (70%) patients. The rate of\nmutation detection varied between different centers (21-100%), with higher rates in the centers employing multiple analytic methods.\"\n\n\n\"To examine the possibility that centers preferentially ascertained probands with the most severe phenotype, we compared risks in the index cases with their relatives. Cancer risks were similar between the two groups indicating that proband selection was not strongly related to the probability\nof a cancer diagnosis (log-rank test of difference m2 = 0.02; 1 df; P = 0.89). Similarly, significant differences were not found in risk according to whether the proband was familial or sporadic (log-rank test of difference m2 = 0.38; 1 df; P = 0.54).\"  \n\nJHM:\nCancer incidence in 419 individuals with PJS, 297 with confirmed mutations in STK11\n96 cancers found\n85 unique mutations (61 truncating, 16 splicing, 4 in-frame deletions in kinase domain, 15 missense all in kinase domain)\nGI cancer 57% by age 60y [39-76 CI]\nBreast cancer 45% [27-68 CI]\nGyn cancer (uterine, ovarian, cervical) 18% by age 60y [9-34 CI]\nPancreas 17% to age 60y [8-36 CI]\nLung 17% to 60y [8-35 CI]\n\n\nJHM: I am scoring this to 2 points for overall malignancy phenotype in PJS. This is one of the larger cohort studies, and tumor incidence is comparable to Lim et al. and Mehenni et al, smaller scale studies.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51659aa8-659d-413a-bd38-a8a924c03156_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16707622","rdfs:label":"Hearle Cohort study","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/54872848-702a-45a0-91f8-f2d5d69626af","type":"Cohort","allGenotypedSequenced":297,"alleleFrequency":0.2188552188552189,"detectionMethod":"\"Several different techniques were\nused by each of the centers to identify germ-line STK11/LKB1\nmutations: conformational sensitive gel electrophoresis, single-strand\nconformational polymorphism, denaturing high-performance liquid\nchromatography, denaturing gradient gelelectrophoresis, and direct sequencing of exons.\"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51659aa8-659d-413a-bd38-a8a924c03156_cc_evidence_item"}],"numWithVariant":65,"relatedCondition":{"id":"obo:MONDO_0008280"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/90a1f212-8797-4c17-b67c-c14302391dd8","type":"Cohort","allGenotypedSequenced":0,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51659aa8-659d-413a-bd38-a8a924c03156_cc_evidence_item"}],"numWithVariant":0},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"Other"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f61b8bd8-8554-48f1-a96a-c083750617c9_proband_segregation","type":"FamilyCosegregation","dc:description":"Family A does not have 4 affected segregations.  Will use the 3 segregations as evidence of gene impact, but not count them for segregation points.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","rdfs:label":"Jenne 1998 Family A","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/f61b8bd8-8554-48f1-a96a-c083750617c9","type":"Family","rdfs:label":"Jenne 1998 Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/527a6139-f2d7-4f20-b3f9-c6a6874ce1f6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","rdfs:label":"Jenne 1998 Proband A","allele":{"id":"https://genegraph.clinicalgenome.org/r/521db840-bdbb-40bc-b9e3-7e5c7f45f27e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"STK11, EX4-5DEL/EX6-7INV","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7438"}},"detectionMethod":"Long distance PCR encompassing exons 4-7 of STK11 gene.","firstTestingMethod":"PCR","phenotypeFreeText":"Phenotypes in text were not individually described, but are described across the set as: \"PJ patients among this sample collection were identified on the basis of available histopathological findings and anamnestic reports of characteristic melanin spots. At least two hamartomatous polyps of the intestine had been investigated for each PJ patient. A family history of PJ disease is documented for patients A, D and MA, but not for patients B and FA. The histopathological criteria of PJ polyps and the characteristic clinical features of the PJ syndrome were met for all five patients\".  ","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/67f7f704-a4e7-4599-bf06-eb44c8e3a944_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","allele":{"id":"https://genegraph.clinicalgenome.org/r/521db840-bdbb-40bc-b9e3-7e5c7f45f27e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/527a6139-f2d7-4f20-b3f9-c6a6874ce1f6"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/67f7f704-a4e7-4599-bf06-eb44c8e3a944","type":"EvidenceLine","dc:description":"Authors state this subject has a family history of Peutz-Jeghers syndrome, and pedigree is in Figure 3A. \n","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67f7f704-a4e7-4599-bf06-eb44c8e3a944_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75e6cff3-0054-4a95-ad8b-001967569295","type":"EvidenceLine","dc:description":"Scored down to 1 as this was a full knock-out and not Heterozygous loss.  (though there was evidence in at least 1 HET mouse that developed mammary gland tumors)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47bea40e-7f57-4a9e-a539-3f7a73972a80","type":"Finding","dc:description":"Loss of Stk11 in mammary glands caused the formation of mammary tumors in mice with histopathological features similar to that of breast tumors in humans with PJS. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19681070","rdfs:label":"McCarthy Mouse model 1","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ab783289-eaf7-4b47-aa11-b5bc727208f1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fdeb9ac0-bea8-484c-90d7-90eb051e7ba4","type":"Finding","dc:description":"Both the heterozygous knockout mice and humans with PJS develop small intestine hamartomatous polyps","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12226664","rdfs:label":"Bardeesy 2002 Animal Model 1","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d3ca312-fa52-44e3-b759-a9b5a61c1f93","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e90508bc-18c6-45af-94ec-e5c76e129b37","type":"FunctionalAlteration","dc:description":"Confirmed using Western blot in HeLa cells that these variants cause a marked decrease of autophosphorylation activity compared to wild-type. these specifically impair the AMPK pathway known to be involved in tumorigenesis and PJS phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15800014","rdfs:label":"In vitro assay Western Blot analysis"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e22f4b56-56d5-48c1-ba9b-3e81654dd203","type":"EvidenceLine","dc:description":"Editing this down to 0.25, to be added to subsequent experiment showing mTOR activation for another 0.25, for a total of 0.5 points this paper.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf20c31f-e4d0-4d5d-bb8f-d71ec6a6272a","type":"FunctionalAlteration","dc:description":"mTor signalling still active under low ATP conditions (Figure 1).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15261145","rdfs:label":"Non-patient cells 1"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/2dc64537-868a-413a-9637-36a65a94c4d1","type":"EvidenceLine","dc:description":"Editing this down to 0.25, to be added to additional experiment showing mTOR activation for another 0.25, for a total of 0.5 points this paper.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/490782c3-3cfb-41b3-9304-4a11eb35d2e4","type":"FunctionalAlteration","dc:description":"Loss of Stk11 in MEFs activates mTor signalling in response to AICAR treatment rather than repressing mTor signalling.  Same phenotype also seen in Stk11 knockout MEFs transfected with kinase-dead mutant Stk11 compared to vector-transfected controls.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15261145","rdfs:label":"Non-patient cells 2"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/89685102-ac40-4932-96e7-c2e9e9280858_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e15fab84-7cf8-4ccc-9815-8d0a1b3a5f08","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68e9d03b-8d6f-41d0-8bc8-85d18a7669c9","type":"Finding","dc:description":"LKB1 fails to phosphorylate targets, leading to cellular problems that contribute to formation of Hamartomatous polyps and breast carcinoma.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15987703","rdfs:label":"Mehenni Biochemical function 1","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/53f78f2d-c469-446e-9d99-288ef182b489","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac47331a-dfd8-4510-bf20-53d630376398","type":"Finding","dc:description":"No other genes studied/assessed in this paper.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10441497","rdfs:label":"In vitro kinase assay and nuclear localization assay","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e2b03d98-ba09-48a4-a228-6dcf3c685d38","type":"EvidenceLine","dc:description":"Since the coIP was conducted on endogenous protein isolated from adult human small intestine, the experts agreed to grant 1 point to this evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7c380156-2635-4ce2-aff9-71beed2db81e","type":"Finding","dc:description":"PTEN is associated with PTEN Hamartoma Syndrome (MIM:601728), which has hamartomas as a clinical feature similar to Puetz-Jeghers Syndrome (MIM:175200). See HPO term HP:0004390.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15987703","rdfs:label":"Mehenni 2005 Protein interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e18b0c41-35b1-4a03-a7d6-82476ddffdf5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7c58937-6353-451b-aca7-bdc536962297","type":"Finding","dc:description":"STK11 detected by northern blot in adult human colon and small intestine.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9425897","rdfs:label":"Jenne 1998 Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":7271,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/txxl_mampH4","type":"GeneValidityProposition","disease":"obo:MONDO_0008280","gene":"hgnc:11389","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_89685102-ac40-4932-96e7-c2e9e9280858-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}